您当前的位置:
首页 >
文章列表页 >
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
REVIEW | 更新时间:2023-02-28
    • The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

    • The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

    • Zaid Sirhan ,Anita Thyagarajan ,Ravi P. Sahu
    • 解放军医学杂志(英文版) 2022年9卷第5期 页码:628-636
    • DOI: 10.1186/s40779-022-00401-3     

      中图分类号:

    移动端阅览

  •  
  •  
  • HTML全文

  • 图( 1 ) 表( 2 )

  • 参考文献

  • 出版信息

  • 数据统计

论文导航
icon
试读结束,您可以激活您的VIP账号继续阅读。
去激活 >
icon
试读结束,您可以通过登录账户,到个人中心,购买VIP会员阅读全文。
已是VIP会员?
去登录 >

19

浏览量

16

下载量

0

CSCD

文章被引用时,请邮件提醒。
提交
工具集
  • BibTeX下载
  • Endnote下载
  • RefMan 下载
  • NoteExpress下载
  • NoteFirst下载

相关文章

Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances
Accelerating global efforts to prevent women’s cancers
Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies
Immunotherapy for tuberculosis: current strategies and future directions
Metal-based nanomedicines for cancer theranostics

相关作者

Gui-Long Tanzhu
Liu Chen
Jiao-Yang Ning
Gang Xiao
Su Wen
Ce Wang
Hao Wen
Ke-Qin Zhang

相关机构

Department of Oncology, Xiangya Hospital, Central South University
Department of Radiation Oncology, Hunan Cancer Hospital/Affiliated Hospital of Xiangya School of Medicine, Central South University
Xiangya Lung Cancer Center, Xiangya Hospital, Central South University
Department of Neuroscience, West Virginia University School of Medicine, Rockefeller Neuroscience Institute
Department of Pharmaceutical Sciences, West Virginia University School of Pharmacy